Trials / Completed
CompletedNCT06277934
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RGT001-075 Compared With Placebo in Adult Patients With Obesity or Overweight With Weight-Related Comorbidities
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Regor Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RGT001-075 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2024-03-08
- Primary completion
- 2024-08-13
- Completion
- 2024-08-13
- First posted
- 2024-02-26
- Last updated
- 2025-08-07
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06277934. Inclusion in this directory is not an endorsement.